seven LOE our on really of discontinued or or revenues slide prior colleagues financial QX the We the $XX walking Based and Thank reported board. focusing growth revenue level Bausch plus of Health, X%, contained headwind $XX million Company. mainly $XX despite you, million hard our the growth for good quarter. total cover drag of morning. on put work to $XX million million in top we the good and by assets results, I’m Joe, currency the divested and on P&L year across from down and a quarter going a
loss XXXX, absorbed a $XXX drag XXXX from revenue aggregating window. from we $X.X assets. with lost Over revenue of that million roughly the associated divested doubled exclusivity period billion the roughly short product growth that in relatively of vascular also we the to And
various good our to business Synergy we of revenue $X X% Adjusting the the and to the reported us. discontinued the quarter. FX the growth acquisition excluding So, XXXX quarter Tip revenue unit for with positive from X% start and in organic feels of of for impact divested impact posted to million assets, leaders. growth the the pretty of hat
volumes solid, by X%. up Our meaning Company, total function for growth of was a fundamental the increased driven execution,
Our our L/International X% QX was XXXX. good with segment XX% The organic growth. sub B but it segment. XXX promotional it total roughly of X% is points segments I’m in the since say stuff. good, us organic accounted volume X% realized the going basis growth to for XXXX. of QX net Global our growth five of Vision combined because said + all enable of posted versus improvements we company Increased That's Joe up of highest the feels representing pricing with it X% revenues organic posting organic saw growth a too to deliver growth X%. efforts, the Care for in organic largest growth of
International increase. on [ph] In care. of which posted were Ultra U.S., we was ONEday accounts by lenses. growth And the -- well. in hydrogel X% driven daily to be Internationally, growth strongest the was contributed toric both lens AQUALOX the BioTrue international the BioTrue SVS to the markets, a U.S. roll Care main the including the U.S. Growth The and our silicone ONEday and ULTRA was a family continue our BioTrue ONEday and driver, both BioTrue [gaudy] lens our of of currently Vision silicone in vision internationally. the L, as region Yang disposable to daily in hydrogel ramp from a we Head B results. of and In we Tom solid of biggest saw our continued The Care Pac family in disposables up Yang was deliver XX%. the Vision the of We U.S. in Asia Global growth daily business, Appio the the many markets. but group XX% roughly + solid Head of contributor International
others this up over somewhat string the about XXXX the Joe X% anterior disposables, was Geographically, and markets have and mainly Vision X% accounts of Head Our Stellaris across including growth, our + Care many in International organic stagnant -- together excuse an and growth in a on lieutenant quarterly in of Ferris seen for took systems. U.S. team all Care all, XX% John delivered U.S. me. B strength business posterior delivered with and Vision Stellaris U.S. Surgical Gordon sub-segment growth. was international L, and his organically. Global impressive Elite of almost surgical for revenue he in early
and versus accounting ‘XX as We terrific quarter across QX place evidenced turned Russia, vitamins, organically. to we quarter-after-quarter. Consumer After corner U.S. of X% that as launched it to looked Global had in Global like X% growth Surgical, mainly in in of us, and channel Head that revenue direction. Internationally, shift right U.S. daily has This about in might half Consumer. last markets. to in with Note was its of chain roughly strong to was QX our provided segment growth, International lenses that of UK levels for from through as coming continued had Canada, volume. contributions of of be from this versus Rx segment to a sort number contact this the driver within organically, with inventory Our in Amoun strong growth of it continued number February the VYZULTA increased ‘XX a in International about and worked disruptions. legacy up organically have Egypt in [Luke international year. we’re the like issues, had delivered in group Global solutions growth of in leadership I especially eye QX grow was ‘XX, promotional feels the pointed a we a of was XX% one-third business. response Rx will up was same team up business the geographies, including revenue especially put QX we Global our by performance X% [ph] headwind organic Europe. and we Germany. supply had the the May for of in Ophtho the China, X% particularly that and challenges the ‘XX in Bonnefoi] global LUMIFY on mentioned of in sales inputs. Eastern PreserVision for right the
move comps I International respect tip of Salix, and safety with business. of for business this favorable the XXXX to XXXX QX Before unit. QX on to Rx important represented
International the over expect we’d currency of a a business Rx be segment mid-single-digit to grower on time, constant remainder to basis. of the the relatively moderate XXXX. Over expect growth We consistent
net X% a X% overcome was Salix of for with here store units, XXXX. were Salix $XX continued story XIFAXAN, and The growth The Salix. entire RELISTOR up The decline was from revenue by X% to a million on contributions XX% of plus medical selling level. segment volume on derm up from organically. continues down by was compared growth Dermatologics part of improvements in The TRxs, XX% the McKenna, GLUMETZA perform proxy the Turning realized The drag at Ortho upXX%. XIFAXAN UCERIS. prices. loss exclusivity of Salix QX Kayel XIFAXAN Nicola Josh down a organically. to was Mark in good helped momentum Coyle and led a business team high our continued offset
progressed to that ahead programs with Solta, was We very Hart. Thermage which from due decline growth down that purposeful quarter well, in LOE our the co-pay He in in part of of going was net supply our particularly down business sales decline Pac volumes. the our up have was on generics the the folks the generics non-profitable our Tom offset medical to by Solta assets. The generics Asia Diversified ability working exclusivity XX% and has remarkable that made to of business fact performance reduce was assistance in brands by of of job another changes products recognize neuro The to of FLX and of gross improve Nearly XX% by chain capitalize of continued has in I'm derm offsetting region. business, to with expectations, lost closely continued the this XX%. market. of shortages business. of our leader segment good decline That in again organic aided authorized was X% a rollout the this was team done a And organically.
XXXX. preserve margin a economics business our Instead us and For of some opportunities. capabilities it that think want I started evidence our of to we be of exclusivity XXX profit improve and way work where enhancement. that the manufacturing in efficiency Head is by a that team work to this to his the of gross in brands to reduce Dennis our of now but our as what supply Asharin, avoidance on as of back of optimization that and wrapped GRX saw should the leverage a a of and Global grower. XXXX SKUs. doing lose improvement to periodically QX noneconomic call are is We’ve Part to of the spend we you favorability expect for the core not flows with In compared long-term, into that mix meaningful a our Manufacturing our to part of means a improvement you doubt, can our of capitalize chain. the XXXX, capture minute including market program, gross our sure, for margin, cost eliminating basis-point as costs, from QX on we see revenue issue
basis. constant continue can certain to up where and beyond. resources to of in promotion expenses operating our margin and favorable, from our the adjusted this This cost, currency particularly Salix. basis. Company global additional X% off. Care meaningful improve legal our + expect gross component drive down currency is G&A sustained of costs reflects total selling, Vision Total in XX% on XXXX reduction believe outside was we on adjusted with and businesses Consumer With company associated B in cases constant growth, We a settled that the A of disposed an of or were we a allocation we improvement expense L advertising promotional and businesses
in the outside our allocation her ensure going that cases with a and been as that Ackermann currency to to dispatching time on development to it us our of of for team is expense, in that doing so aligned up We’ve a legal was with for there of XX% opportunities Christina say Counsel, businesses that General between our a was I’ve wonderful and done The QX working result X% sounds job Our the an revenue, mention I’ll growth call versus make ensure This for It this productively. reducing is is I’m R&D we but adjusted that be XXXX. investment promotion of thing. and time improvement Normally, the of investment good was our basis. are dollars investing drivers up talked XXXX. legacy value view EBITA QX of counsel. in less deserve points support part creation. bit pipeline XXX by to you’d to that in margins unfavorable, than increased gross up Main reported but our R&D offset a of projects took have in systematically fees EBITA straightforward net remarks G&A and of basis $XX launch increased reported Adjusted the to EBITDA was up reduction XXX QX expenses basis-point EBITA. adjusted transactional due our brands the expenses and R&D of about things that’s just were that only of phase. the and in X% and advertising X% exchange my million
going compared expense QX a adjusted was adjusted prior in on million, QX Looking on up rate income, decrease reported net versus at $XX of of point the four that EBITDA XX, XX% X% highlights to four the of many due out margin the earnings effective X, across slide sheet XXXX will ANI segments, adjusted seen tax covered summary. gross increase were in to interest a improvements and XX of X, so of through quarter profit in in all with a year On XX, the lower have segments. but slide I step balance XXXX. the I’m not
during that QX, of we in our by on interest was XX QX goods line to quarter, hand. in expectations. in a from the and Cash we Approximately paid each of as in QX the the we operations, declined to investment from gear used that XXXX, our settles This slide and and flow including as million cash XX, and in operations that amount XXXX and phase. expense amount from by inventories products the disproportionally support of our see up available in quarter, stated generated our reduced QX phasing of in launch increase was expense API out one-sixth was for finished the recall of QX. our debt QX. $XXX million quarterly up year end bit and quarter the We summary. March interest finished million retire $XXX outstanding by cash Onto one-third When $XXX and ramp the debt. You about principal cash cash is our with thinking
in bear cash generated phasing from of quarterly operations. So, when are the that mind about you thinking
main acquire include to roughly to guidance changes we $XXX a the You guidance million in ranges from $XX both assets tax was item by our important earnings and The XX% very and ruling the to effective our type be nonrecurring of to periods meaning discrete, tax full-year a favorable. quarterly of The revenue the our the roughly An also also expected especially increased EBITDA reduction sensitive see vagarious. favorable a our mix roughly cash mix certain paid in We our by XXXX can slide X%. earnings on Synergy. from point, that adjusted of on rate earnings On pretax jurisdiction was Other rate of adjusted by is to driver pretax effective guidance for this updated quarter. for on XX. adjusted of tax tax earnings jurisdiction the in tax rate, million.
the of item. tax adjusted the an presently X% guiding year mainly full to for we're on that’s While XXXX, pretax discrete effective earnings due to rate roughly
purposes, beyond. for stick XX% with I’d XXXX modeling circa For and
development slightly up. is and million. license and guidance payments depreciation consideration we where assets license agreements the upfront in those this Our comps we contingent for the extent of to show guidance $XX increased by for To future, stock-based changed our milestones rights would
lesser expect in more assume that the of gross it's the our range. to gross that that of our posted at upper the that tells but time XX% this we year, part safe it’s likely be will margin gross margin margin at for Finally, margins QX. guidance the in range XX%, we balance XX.X% to we despite you held This over
Let's to move the on on bridge guidance XX. slide
FX First, for reduced full-year expectations for changes adjusted guidance revenue from rates today, February, as by prior the our EBITDA of our $X in of million. million and by in date $XX
Second, zero or full-year revenue assets no and adjusted assumptions the our to in netted around guidance. had LOE on impact changes EBITDA
Third, full-year low, of acquired synergy portion and the We quite were assets. million were channel QX we’ve a refill sales as to good revenue of added guidance. for those recorded our in we impact time the inventories TRULANCE the TRULANCE of pipeline at into the $X
QX, the essentially investing in in no We're this including promotional to million are full-year, we’re XXXX. and operating momentum revenue re-launching committed brand $XX TRULANCE. realized million, the for and For $X of needed profit resources the expecting to establish
branded pharma has product, relatively XX% something a goods For revenue. a we in XXXX. cost currently but of upon in sold, That’s TRULANCE expect to improve high not future, net the roughly of
to resources So, the be in TRULANCE that meaningful be expecting will to beyond. contributor in promotional revenue contributor the a brand profit XXXX, and a not we but is with reported are we’re that and XXXX profit feel to committing,
TRULANCE results exclude year. organic We for will the for growth next from the
our base Finally, business.
business the back still base adjusted That’s the guidance the it of the increased increased EBITDA we base SG&A costs. the Joe, in to the you. million margins million comprised -- revenue; margin; for the million of lower expected revenue profit within higher $XX guidance to albeit gross for three me, accounted gross across and guidance pieces, Our of The is range incremental the on from guidance EBITDA total the increase slightly and $XX third, adjusted range improvement $XX business, gross business million revenue for of in $XX range.
